Recent News

• 09.05.2025 - Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
• 07.31.2025 - Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
• 07.22.2025 - Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
• 07.09.2025 - Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Recent Filings

• 08.28.2025 - EFFECT Notice of Effectiveness
• 08.18.2025 - DEF 14A Other definitive proxy statements
• 08.15.2025 - S-3 Registration statement under Securities Act of 1933
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2025 - PRE 14A Other preliminary proxy statements
• 07.25.2025 - 8-K Current report
• 07.25.2025 - EX-99.1 EX-99.1
• 07.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2025 - 3 Initial statement of beneficial ownership of securities